Your browser doesn't support javascript.
loading
Protein kinase C -activating isophthalate derivatives mitigate Alzheimer's disease-related cellular alterations.
Sarajärvi, T; Jäntti, M; Paldanius, K M A; Natunen, T; Wu, J C; Mäkinen, P; Tarvainen, I; Tuominen, R K; Talman, V; Hiltunen, M.
Afiliação
  • Sarajärvi T; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Jäntti M; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Paldanius KMA; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Natunen T; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Wu JC; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Mäkinen P; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland.
  • Tarvainen I; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Tuominen RK; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Electronic address: raimo.tuominen@helsinki.fi.
  • Talman V; Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Hiltunen M; Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. Electronic address: mikko.hiltunen@uef.fi.
Neuropharmacology ; 141: 76-88, 2018 10.
Article em En | MEDLINE | ID: mdl-30138694
ABSTRACT
Abnormal protein kinase C (PKC) function contributes to many pathophysiological processes relevant for Alzheimer's disease (AD), such as amyloid precursor protein (APP) processing. Phorbol esters and other PKC activators have been demonstrated to enhance the secretion of soluble APPα (sAPPα), reduce the levels of ß-amyloid (Aß), induce synaptogenesis, and promote neuroprotection. We have previously described isophthalate derivatives as a structurally simple family of PKC activators. Here, we characterised the effects of isophthalate derivatives HMI-1a3 and HMI-1b11 on neuronal viability, neuroinflammatory response, processing of APP and dendritic spine density and morphology in in vitro. HMI-1a3 increased the viability of embryonic primary cortical neurons and decreased the production of the pro-inflammatory mediator TNFα, but not that of nitric oxide, in mouse neuron-BV2 microglia co-cultures upon LPS- and IFN-γ-induced neuroinflammation. Furthermore, both HMI-1a3 and HMI-1b11 increased the levels of sAPPα relative to total sAPP and the ratio of Aß42/Aß40 in human SH-SY5Y neuroblastoma cells. Finally, bryostatin-1, but not HMI-1a3, increased the number of mushroom spines in proportion to total spine density in mature mouse hippocampal neuron cultures. These results suggest that the PKC activator HMI-1a3 exerts neuroprotective functions in the in vitro models relevant for AD by reducing the production of TNFα and increasing the secretion of neuroprotective sAPPα.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Ftálicos / Doença de Alzheimer Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Neuropharmacology Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácidos Ftálicos / Doença de Alzheimer Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Neuropharmacology Ano de publicação: 2018 Tipo de documento: Article